Spanish Health Ministry to Fund Generic Version of "Champix"

Regulations by 2FIRSTS.ai

May.30.2024

Spanish Health Ministry to Fund Generic Version of "Champix"

Spain's Health Ministry to fund generic version of "Champix" from June, after original version pulled due to impurities.

According to El Mundo on May 29th, the Spanish Ministry of Health will start funding generic versions of "Champix" from June, a drug that was previously removed from the market due to impurities found in the production process of its main component, Varenicline.

Susana Verdejo, director of the Tobacco Prevention and Control Department at the Spanish Ministry of Health, revealed during a World No Tobacco Day meeting on Wednesday (May 29) that the active ingredient varenicline in the pharmaceutical giant Pfizer's drug "Champix" was ordered to be removed from shelves in 2021 by the Spanish Agency of Medicines and Medical Devices (AEMPS) due to the presence of carcinogenic nitrosamine impurities above permitted levels during the manufacturing process. It is expected that in June, the version of the drug produced by the designated manufacturer Normon will be available for sale in Spanish pharmacies.

In Spain, two smoking cessation medications, "Todacitán" and "Recigarum," have received funding. Therefore, there are currently three smoking cessation medications available in Spain.

References:

[1] Sanidad financiará vareniclina, el genérico de 'Champix', como tratamiento para dejar de fumar a partir de junio

Also Read:

[1] British Tourists Face £1,700 Fine for E-Cigarettes in Spain

[2] Spanish Tobacco Prevention Committee Urges Generic Packaging for Tobacco Products

[3] Spanish National Smoking Prevention Plan to be Implemented by Year End

[4] Spain Approves New Smoking Ban Plan with Increased Taxes

[5] Canary Islands Considering Comprehensive Smoking Ban Legislation for Public Health

[6] UK Approves Sale of Promising Smoking Cessation Medication, Cytisine

#Europe #Traditional tobacco #Spain #Regulation

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

iMiracle and VPR Reach Preliminary Settlement in ‘Elf’ Trademark Dispute, Potentially Ending Three-Year Legal Battle

According to Law360, VPR Brands and iMiracle have filed a joint notice in federal court in Florida stating that they have signed a settlement term sheet and plan to finalize a global settlement within 30 days that would resolve multiple lawsuits. The dispute, which began in 2022 and centers on the “Elf” trademark, has involved injunctions, counterclaims and a key ruling by the Federal Circuit overturning a lower court’s order.

Dec.11 by 2FIRSTS.ai

Moroccan Government Rejects Opposition Proposal to Increase Excise Tax on E-Cigarettes

Moroccan government has firmly rejected proposals from opposition parties to increase the internal consumption tax (TIC) on e-cigarettes and related products under the 2026 Finance Bill. Budget Minister Delegate Fouzi Lekjaa argued that raising excise duties would not reduce demand and would instead encourage smuggling. Opposition groups emphasized the growing health risks and rising popularity of vaping among young people.

Nov.13 by 2FIRSTS.ai

BAT accused of “utter hypocrisy” over efforts to dilute Zambia’s tobacco bill

The Guardian reports that British American Tobacco urged Zambian ministers to drop or delay ad and sponsorship bans and to soften a draft tobacco bill by shrinking health warnings, easing flavour restrictions and lowering penalties. Critics said the stance is hypocritical given similar rules apply in the UK.

Nov.13

PMI Japan Unveils Limited-Edition IQOS ILUMA i “Galaxy Blue,” Priced Around $47

Philip Morris Japan announced it will release the limited-edition IQOS ILUMA i “Galaxy Blue” across IQOS stores nationwide starting October 29, priced at JPY 6,980 including tax (about USD 47). The new model features a space-themed design, with a members-only promotion to run at the Nagoya IQOS store.